Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025. [PDF]
ABSTRACT Developed at Bayer Technology Services, PK‐Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open‐source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open‐source model‐informed drug development (MIDD). This
Cordes H +35 more
europepmc +2 more sources
The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development [PDF]
Computer-based (in silico) modeling & simulation tools have been embraced in different fields of pharmaceutics for a variety of applications. Among these, physiologically-based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a ...
Cvijić Sandra +3 more
doaj +1 more source
Prediction and Prognostication of Peripheral Blood Biomarkers in Head and Neck Cutaneous Squamous Cell Carcinoma. [PDF]
Abstract Objective While many with head and neck cutaneous squamous cell carcinomas (cHNSCC) respond well to surgery alone, there is a need to refine traditional staging systems. We aim to identify whether peripheral blood biomarkers (PBBMs) may enhance current staging for prognostication and adjuvant treatment selection.
Hubbard MG +7 more
europepmc +2 more sources
Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling. [PDF]
ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic cornerstone of model‐informed drug development (MIDD), providing evidence for regulatory decisions. PBPK models integrate physiological and pharmacological data and have been applied across a plethora of contexts of use, including assessing drug–drug interactions (DDIs ...
Chenel M +6 more
europepmc +2 more sources
Subcutaneous Biopharmaceutics: Building tools for a flexible future
The major biopharmaceutics challenge faced during the development of subcutaneous (SC) drug products is the limited understanding of the physiological factors and the combination product attributes that can impact absorption rate/extent and drug product ...
Kate Louise Harris +4 more
doaj +1 more source
Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions. [PDF]
Pharmaceutical innovators and generic companies use Physiologically Based Biopharmaceutics Models (PBBMs) to guide drug product development and potentially waive clinical pharmacokinetic studies for both pre- and post-approval changes.
Arora S +23 more
europepmc +2 more sources
Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference. [PDF]
ABSTRACT In 2017, the free and open‐source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open‐source solutions for model‐informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in
Dallmann A +31 more
europepmc +2 more sources
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report. [PDF]
36973731This Article shares the proceedings from the August 29th, 2023 (day 1) workshop “Physiologically Based Biopharmaceutics Modeling (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives”.
Pepin X +39 more
europepmc +4 more sources
Abstract This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG). The aims of this
Fang Wu +17 more
wiley +1 more source
Abstract Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution retrospective cohort study, a dataset of patients with
Cassie Pan +13 more
wiley +1 more source

